CDXI
Healthcare BiotechnologyCardax, Inc.
$0.00
+0.00 +0.00% today
Price History
Not enough data
Key Stats
Market Cap
80.252
Avg Volume
17
EPS
-$3.54
52W High
$0.00
52W Low
$0.00
Div. Yield
0.0%
Valuation
Forward P/E
-0.00
P/B Ratio
-0.00
P/S Ratio
0.00
EV/EBITDA
-1.84
EV/Revenue
10.65
Margins
Gross Margin 65.7%
Operating Margin (737.6%)
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Revenue Growth (YoY)
(26.8%)
Return on Assets
(112.6%)
Liquidity & Leverage
Current Ratio
0.09
Quick Ratio
0.01
Total Cash
61,713
Total Debt
5.40M
About
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
www.cardaxpharma.com